Usama Malik's guest appearances

Usama Malik

CFO THOUGHT LEADER

Empowered Patient Podcast

Aerami Therapeutics

Bioxcel Therapeutics

Amolyt Pharma

Anixa Biosciences

Sensus Healthcare

Matt Murphy

Robin Smith

Thomas Cowan

Rajesh Gupta

Dave Jones

Greg Miller

Travis Mickle

Justin Miller

Jeff Epstein

John Collins

OwlTail

Usama Malik, CEO, Fore Biotherapeutics is aiming to treat patients with rare cancer mutations with a hyper targeted precision or personalized approach by using the Fore AI-based technology platform to investigate which drugs might work best for each mutation. While most cancer companies focus only on the most prevalent mutations, Fore is expanding the search by looking at hundreds of mutations to identify driver mutations that actively contribute to the growth of tumors. Fore is in search of unaddressed patient populations and patients where existing therapeutics are not working. #ForeBiotherapeutics #cancer #raredisease #oncology #BRAF #precisionmedicine #personalizedmedicine #DriverMutations Fore.Bio Download the transcript here

Usama Malik, CEO, Fore Biotherapeutics is aiming to treat patients with rare cancer mutations with a hyper targeted precision or personalized approach by using the Fore AI-based technology platform to investigate which drugs might work best for each mutation. While most cancer companies focus only on the most prevalent mutations, Fore is expanding the search by looking at hundreds of mutations to identify driver mutations that actively contribute to the growth of tumors. Fore is in search of unaddressed patient populations and patients where existing therapeutics are not working. #ForeBiotherapeutics #cancer #raredisease #oncology #BRAF #precisionmedicine #personalizedmedicine #DriverMutations <a href="http://fore.bio" rel="noopener nofollow" target="_blank">Fore.Bio</a> <a href="http://empoweredpatientradio.com/moving-from-precision-medicine-to-personalized-drugs-to-fight-driver-mutations-in-cancer-with-usama-malik-fore-biotherapeutics-transcript" rel="noopener nofollow" target="_blank">Download the transcript here</a>

Moving from Precision Medicine to Personalized Drugs to  Fight Driver Mutations in Cancer with Usama Malik Fore Biotherapeutics

Usama Malik, Chief Financial Officer and Chief Business Officer, Immunomedics discusses the challenges of developing effective medicines for people with triple negative breast cancer as well as Immunomedics' development of antibody-drug conjugates, directed therapies which have potential to provide new options for those with hard to treat cancers. @immunomedicsinc #breastcancer  #TNBC  #HER2  #TripleNegative  #bladdercancer  #urothelial Immunomedics.com Download the transcript here

Usama Malik, Chief Financial Officer and Chief Business Officer, Immunomedics discusses the challenges of developing effective medicines for people with triple negative breast cancer as well as Immunomedics' development of antibody-drug conjugates, directed therapies which have potential to provide new options for those with hard to treat cancers. @immunomedicsinc #breastcancer  #TNBC  #HER2  #TripleNegative  #bladdercancer  #urothelial <a href="http://Immunomedics.com" rel="noopener nofollow" target="_blank">Immunomedics.com</a> <a href="http://empoweredpatientradio.com/targeting-specific-proteins-to-treat-triple-negative-breast-cancer-with-usama-malik-immunomedics-transcript" rel="noopener nofollow" target="_blank">Download the transcript here</a>

Targeting Specific Proteins to Treat Triple Negative Breast Cancer with Usama Malik Immunomedics

“It’s the economics, the finance,” says CFO Usama Malik, who quickly adds the words “and the accounting” to his short list of finance leader action items. Malik begins where most CFOs end–with the economics behind the business model. Everything else follows, he explains.   “This role is about applying a broader lens to an entire industry and figuring out a competitive advantage,” adds Malik, who, while bullish on the science behind Immunomedics’ future offerings, makes clear his contention that it’s the economics that will ultimately determine the company’s fate. “Historically, there have been fund-raising CFOs, operational CFOs, and strategic CFOs. … I’ve now started to combine these disciplines, and the culmination of these is really advancing the role,” explains Malik. –Jack Sweeney   

“It’s the economics, the finance,” says CFO Usama Malik, who quickly adds the words “and the accounting” to his short list of finance leader action items. Malik begins where most CFOs end–with the economics behind the business model. Everything else follows, he explains.   “This role is about applying a broader lens to an entire industry and figuring out a competitive advantage,” adds Malik, who, while bullish on the science behind Immunomedics’ future offerings, makes clear his contention that it’s the economics that will ultimately determine the company’s fate. “Historically, there have been fund-raising CFOs, operational CFOs, and strategic CFOs. … I’ve now started to combine these disciplines, and the culmination of these is really advancing the role,” explains Malik. –Jack Sweeney